The regulatory green light covers treatment for acute uncomplicated influenza and post-exposure prevention in patients aged 5 and older. By introducing a generic competitor, federal health officials aim to curb rising pharmaceutical costs and broaden patient access to the medication. This approval follows the agency's stated strategy of fostering market competition to ensure that essential antiviral treatments remain within reach for a wider demographic as seasonal outbreaks persist.